Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of them 10 stocks investors are watching closely this week.
Iovance rose 32.9 percent on the week to a new all-time high after analysts doubled its price target for the stock, while investors loaded portfolios ahead of trading updates next week.
In its market report, investment firm UBS rated Iovance Biotherapeutics Inc. (NASDAQ: IOVA ) raised its price target to $4 from $2, but maintained a “neutral” rating on the stock.
Image from Iovance Biotherapeutics website
The coverage came ahead of the biopharmaceutical company’s participation in the 28th annual Barclays Global Healthcare Conference on Wednesday, March 11, where investors will be looking at appetite and company developments to support buying appetite.
In other news, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) recently reported a 5 percent wider net loss in 2024 to $390.98 million, compared to $372 million in 2024. On the other hand, total revenues rose 60.6 percent to $263.5 million from $164.07 to $164 million.
In the fourth quarter alone, net loss fell 8 percent to $71.9 million from $78.5 million in the same period last year, while revenue rose 17.6 percent to $86.7 million from $73.69 million year over year.
While we recognize IOVA’s potential as an investment, our belief is that some AI stocks have more promise to deliver higher returns and have limited risk. If you’re looking for a very cheap AI stock that’s also a big beneficiary of Trump’s tariffs and onsuring, check out our free report Best short-term AI stocks.
Read more: 30 stocks that should double in 3 years and 11 Secret AI Stocks to Buy Right Now.
Disclosure: None. Follow the inside port on Google News.
